このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

HR陽性、HER2陰性の再発または転移性乳がん患者における内分泌療法と併用したアリセルチブの研究 (ALISCA-Breast1)

2026年9月28日 更新者:Puma Biotechnology, Inc.

HR+、HER2陰性の再発または転移性乳がん患者における内分泌療法と併用したアリセルチブの第2相試験

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy. Participants randomized prior to Amendment 4 are randomized 1:1:1 to Arm 1, Arm 2 or Arm 3. Participants randomized under Amendment 4 will be randomized 1:1 to Arm 1 or Arm 2.

調査の概要

研究の種類

介入

入学 (推定)

225

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、34235
        • 募集
        • Alabama Oncology
    • Arizona
      • Phoenix、Arizona、アメリカ、85054
        • 募集
        • Mayo Clinic Hospital
    • California
      • Beverly Hills、California、アメリカ、90211
        • 募集
        • Beverly Hills Cancer Center
      • Fountain Valley、California、アメリカ、92708
        • 募集
        • MemorialCare Orange Coast Medical Center
      • Irvine、California、アメリカ、92618
        • 募集
        • City of Hope at Orange County Lennar Foundation Cancer Center
      • Los Angeles、California、アメリカ、90095
        • 募集
        • UCLA Department of Medicine - Hematology/Oncology
      • Los Angeles、California、アメリカ、90017
        • 募集
        • LA Cancer Network
      • San Francisco、California、アメリカ、94158
        • 募集
        • University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • 募集
        • University of Colorado School of Medicine
    • Connecticut
      • New Haven、Connecticut、アメリカ、06520
        • 引きこもった
        • Yale University, Yale Cancer Center
    • Florida
      • Jacksonville、Florida、アメリカ、32256
        • 募集
        • Cancer Specialists of North Florida
      • Jacksonville、Florida、アメリカ、32224
        • 募集
        • Mayo Clinic Florida
      • Tampa、Florida、アメリカ、33612
        • 募集
        • Moffitt Cancer Center
    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • 募集
        • Winship Cancer Institute, Emory University
    • Illinois
      • Chicago、Illinois、アメリカ、60612
        • 募集
        • University of Illinois Cancer Center
      • Chicago、Illinois、アメリカ、60637
        • 募集
        • The University of Chicago
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02114
        • 募集
        • Massachusetts General Hospital
      • Boston、Massachusetts、アメリカ、02215
        • 募集
        • Dana-Farber Cancer Institute
    • Minnesota
      • Minneapolis、Minnesota、アメリカ、55455
        • 募集
        • University of Minnesota, Masonic Cancer Center
      • Rochester、Minnesota、アメリカ、55905
        • 募集
        • Mayo Clinic
    • Missouri
      • Columbia、Missouri、アメリカ、65201
        • 募集
        • Missouri Cancer Associates
      • Kansas City、Missouri、アメリカ、64111
        • 募集
        • Saint Luke's Cancer Institute
      • Springfield、Missouri、アメリカ、65807
        • 募集
        • Oncology Hematology Associates
      • St Louis、Missouri、アメリカ、63110
        • 募集
        • Washington University School of Medicine
    • Nevada
      • Reno、Nevada、アメリカ、89511
        • 募集
        • Cancer Care Specialists
    • New York
      • Rochester、New York、アメリカ、14642
        • 募集
        • University of Rochester Medical Center
    • North Carolina
      • Chapel Hill、North Carolina、アメリカ、27514
        • 募集
        • UNC Hospitals, University of North Carolina at Chapel Hill
    • Ohio
      • Columbus、Ohio、アメリカ、43212
        • 募集
        • The Ohio State University, Stefanie Spielman Comprehensive Breast Center
      • Maumee、Ohio、アメリカ、43537
        • 募集
        • Taylor Cancer Research Center
    • Pennsylvania
      • Horsham、Pennsylvania、アメリカ、19044
        • 募集
        • Alliance Cancer Specialists
      • Philadelphia、Pennsylvania、アメリカ、19104
        • 募集
        • University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine
      • Pittsburgh、Pennsylvania、アメリカ、15213
        • 募集
        • University of Pittsburgh (UPMC)
    • Tennessee
      • Nashville、Tennessee、アメリカ、37203
        • 募集
        • Tennessee Oncology, Greco-Hainsworth Center for Research
    • Texas
      • Dallas、Texas、アメリカ、75246
        • 募集
        • Texas Oncology
    • Virginia
      • Richmond、Virginia、アメリカ、23229
        • 募集
        • Virginia Cancer Institute
      • Alicante、スペイン、03010
        • 募集
        • Hospital General Universitario Dr. Balmis
      • Barakaldo、スペイン、48903
        • 募集
        • Hospital Universitario de Cruces
      • Barcelona、スペイン、08035
        • 募集
        • Hospital Universitario Vall d'Hebron
      • Barcelona、スペイン、08036
        • 募集
        • Hospital Clínico de Barcelona
      • Bilbao、スペイン、48013
        • 募集
        • Hospital Universitario de Basurto
      • Cáceres、スペイン、10003
        • 募集
        • Hospital San Pedro de Alcántara
      • Granada、スペイン、18012
        • 募集
        • Hospital San Cecilio
      • Huelva、スペイン、21005
        • 募集
        • Hospital Universitario Juan Ramon Jimenez
      • Jaén、スペイン、23007
        • 募集
        • Hospital Universitario de Jaén
      • Lleida、スペイン、25198
        • 募集
        • Hospital Universitario Arnau de Vilanova
      • Madrid、スペイン、28040
        • 募集
        • Hospital Universitario Fundación Jiménez Díaz
      • Seville、スペイン、41013
        • 募集
        • Hospital Universitario Virgen del Rocío
      • Valencia、スペイン、46010
        • 募集
        • Hospital Clínico Universitario de Valencia
      • Valencia、スペイン、46009
        • 募集
        • Fundación Instituto Valenciano de Oncología (IVO)
      • Lisbon、ポルトガル、1998-018
        • 募集
        • Hospital CUF Descobertas
      • Lisbon、ポルトガル、1099-023
        • 募集
        • Instituto Português de Oncologia de Lisboa Francisco Gentil (IPO Lisboa)
      • Lisbon、ポルトガル、1400-038
        • 募集
        • Fundação Champalimaud
      • Porto、ポルトガル、4200-072
        • 募集
        • Instituto Português Oncologia Do Porto

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Aged ≥18 years at signing of informed consent.
  • Pathology-confirmed diagnosis of breast cancer with evidence of recurrent or metastatic disease not amenable to curative therapy.
  • Progression on or after treatment with at least two prior lines of endocrine therapy in the recurrent or metastatic setting. a. If metastatic disease recurrence occurs during or within six months of discontinuing adjuvant endocrine therapy, then that endocrine therapy will count as one line of prior therapy.
  • Participants must have received a CDK4/6i in combination with endocrine therapy in the recurrent or metastatic setting.
  • HR-positive and HER2-negative tumor status reported per local laboratory testing. HR and HER2 testing must be performed consistent with current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) or European Society of Medical Oncology (ESMO) guidelines.

Exclusion Criteria:

  • Treatment with chemotherapy in the recurrent or metastatic setting, including antibody drug conjugates with a chemotherapeutic payload.
  • Prior treatment with an Aurora Kinase A (AURKA) specific-targeted or pan-Aurora-targeted agent, including alisertib, in any setting.

Note: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Alisertib 50 mg

Alisertib with selected endocrine therapy

Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.

他の名前:
  • MLN8237
  • PB-8237

Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information.

1 mg of anastrozole tablet by mouth once daily or

2.5 mg of letrozole tablet by mouth once daily or

25 mg of exemestane tablet by mouth once daily or

20 mg of tamoxifen tablet by mouth once daily or

500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter

実験的:Alisertib 40 mg

Alisertib with selected endocrine therapy

Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.

他の名前:
  • MLN8237
  • PB-8237

Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information.

1 mg of anastrozole tablet by mouth once daily or

2.5 mg of letrozole tablet by mouth once daily or

25 mg of exemestane tablet by mouth once daily or

20 mg of tamoxifen tablet by mouth once daily or

500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter

実験的:Alisertib 30 mg

Alisertib with selected endocrine therapy

Cohort closed to enrollment in Amendment 4

Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.

他の名前:
  • MLN8237
  • PB-8237

Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information.

1 mg of anastrozole tablet by mouth once daily or

2.5 mg of letrozole tablet by mouth once daily or

25 mg of exemestane tablet by mouth once daily or

20 mg of tamoxifen tablet by mouth once daily or

500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Objective Response Rate (ORR) Within Dose Subgroup
時間枠:From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months

Objective response rate is defined as the percentage of participants demonstrating a confirmed objective response during the study.

From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
Duration of Response (DOR) Within Dose Subgroup
時間枠:From start date of response (after date of randomization) to first PD, assessed up to 48 months

Duration of response is measured from the time at which measurement criteria are first met for Complete Response (CR) or Partial Response (PR) (whichever status is recorded first) until the first date of recurrence or progressive disease (PD) or death is objectively documented.

From start date of response (after date of randomization) to first PD, assessed up to 48 months
Disease Control Rate (DCR) Within Dose Subgroup
時間枠:From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months

Disease control rate is the proportion of participants who achieve overall tumor response (confirmed CR or PR) or Stable Disease (SD) lasting for at least 24 weeks from randomization.

From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
Progression Free Survival (PFS) Within Dose Subgroup
時間枠:From date of randomization to date of recurrence, progression or death, assessed up to 48 months

Progression Free Survival (PFS) is measured in months and based on the local tumor assessment. The time interval from the date of randomization until the first date on which recurrence, progression, or death due to any cause, is documented.

From date of randomization to date of recurrence, progression or death, assessed up to 48 months
Overall Survival (OS) Within Dose Subgroup
時間枠:From date of randomization to death, assessed up to 48 months

Overall survival (OS) is defined as the time from randomization to death due to any cause, censored at the last date known alive on or prior to the data cutoff employed for the analysis, whichever was earlier.

From date of randomization to death, assessed up to 48 months
Percentage of Participants With Treatment-Emergent Adverse Events (Adverse Events and Serious Adverse Events) in the Enrolled Population
時間枠:From date of first dose through last dose plus 28 days, assessed up to 48 months

Treatment emergent adverse events are those events reported on or after the first dose of investigational product and up to 28 days after last dose.

From date of first dose through last dose plus 28 days, assessed up to 48 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Objective Response Rate (ORR) Within Biomarker-Defined Subgroup
時間枠:From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months

Objective response rate is defined as the percentage of participants demonstrating a confirmed objective response during the study.

From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
Duration of Response (DOR) Within Biomarker-Defined Subgroup
時間枠:From start date of response (after date of randomization) to first PD, assessed up to 48 months

Duration of response is measured from the time at which measurement criteria are first met for CR or PR (whichever status is recorded first) until the first date of recurrence or progressive disease (PD) or death is objectively documented.

From start date of response (after date of randomization) to first PD, assessed up to 48 months
Disease Control Rate (DCR) Within Biomarker-Defined Subgroup
時間枠:From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months

Disease control rate is the proportion of participants who achieve overall tumor response (confirmed CR or PR) or SD lasting for at least 24 weeks from randomization.

From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
Progression Free Survival (PFS) Within Biomarker-Defined Subgroup
時間枠:From date of randomization to date of recurrence, progression or death, assessed up to 48 months

Progression Free Survival (PFS) is measured in months and based on the local tumor assessment. The time interval from the date of randomization until the first date on which recurrence, progression, or death due to any cause, is documented.

From date of randomization to date of recurrence, progression or death, assessed up to 48 months
Overall Survival (OS) Within Biomarker-Defined Subgroup
時間枠:From date of randomization to death, assessed up to 48 months

Overall survival (OS) is defined as the time from randomization to death due to any cause, censored at the last date known alive on or prior to the data cutoff employed for the analysis, whichever was earlier.

From date of randomization to death, assessed up to 48 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Chief Reg Affairs, PV, Medical Affairs and Law Officer、Puma Biotechnology, Inc.

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年11月19日

一次修了 (推定)

2027年12月30日

研究の完了 (推定)

2029年6月30日

試験登録日

最初に提出

2024年4月12日

QC基準を満たした最初の提出物

2024年4月12日

最初の投稿 (実際)

2024年4月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月1日

QC基準を満たした最後の更新が送信されました

2026年9月28日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Puma Biotechnology is committed to sharing clinical trial data and information to help physicians and patients make informed treatment decisions, and to help qualified researchers advance scientific knowledge.

In accordance with legal and regulatory requirements, Puma publishes study protocol information and clinical study results on clinical trial registries, including ClinicalTrials.gov and EU Clinical Trials Register. Puma also publishes information about clinical studies in peer-reviewed scientific journals and shares data in scientific meetings.

Puma commits to safeguarding confidentiality and patient privacy throughout the clinical trial data and information sharing process. Any patient-level data will be anonymized to protect personally identifiable information.

Qualified researchers and study participants may submit requests for other study documentation and clinical trial data to clinicaltrials@pumabiotechnology.com for consideration.

IPD 共有時間枠

Clinical study documents and clinical trial data may be requested by qualified researchers and study participants for studies that have been completed for at least 18 months, and for which the indication of the drug has been approved in the US and/or EU, as applicable. Requests will be accepted for up to 24 months after the criteria described in this section are met.

IPD 共有アクセス基準

Requestors must provide organizational contact information; a detailed research plan, including outcomes; timeline for completion of the research; qualifications of the research team; funding source; and potential conflicts of interest.

Puma will not provide access to patient-level data if there is a reasonable likelihood that individual patients could be identified, or in cases where confidentiality or consent provisions prohibit transfer of data or information to third parties. Additionally, Puma will not disclose information that jeopardizes intellectual property rights or divulges confidential commercial information.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する